PENPenumbra exhibits strong fundamentals with consistent revenue and EPS growth, coupled with a healthy balance sheet. Thematic tailwinds in medical devices and neurotechnology are positive, but current valuation metrics and mixed technical signals warrant a 'Buy' rating with a cautious approach.
Penumbra is well-positioned within the growing medical device market, particularly in neurovascular and peripheral vascular intervention. Advancements in medical technology and an aging global population provide strong secular tailwinds.
Penumbra demonstrates robust revenue and EPS growth, with improving profitability and a solid balance sheet. While valuation multiples appear high, the company's financial health and growth trajectory support a positive fundamental outlook.
The stock is trading below its 52-week high and recent moving averages, indicating some short-term weakness. While oscillators suggest potential for a bounce, the overall trend appears to be consolidating or slightly bearish in the short term.
| Factor | Score |
|---|---|
| Medical Device Innovation | 85 |
| Healthcare Spending Trends | 80 |
| Competitive Landscape | 70 |
| Regulatory Environment | 75 |
| Demographic Shifts | 85 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 70 |
| Growth | 85 |
| Balance Sheet Health | 85 |
| Cash Flow | 75 |
| Earnings Consistency | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 65 |
| Short-term Oscillators | 70 |
Positive Earnings Surprise History
Penumbra (PEN) has a history of positive EPS surprises, with the last four quarters showing actual EPS exceeding estimates by an average of 34.5%. This suggests strong operational execution and potentially underestimated future performance.
Strong Cash Position
As of Q4 2024, Penumbra has $324.40 million in cash equivalents, significantly exceeding its total liabilities of $382.25 million when considering current liabilities. The company has maintained positive free cash flow in recent annual periods, indicating good cash generation capabilities.
High Trailing P/E Ratio
The trailing P/E ratio is 213.13 (TTM), and for the latest reported year (2024), it's 656.3. These are exceptionally high multiples, suggesting that the company's current earnings do not justify its market valuation without significant future growth.
Negative Net Income in Recent Quarter
Penumbra reported a net loss of -$6.02 million in Q2 2024, with a net margin of -20.1%. This is a significant deterioration from previous quarters and raises concerns about short-term profitability.
July 2025
30
Next Earnings Date
H: $0.90
A: $0.82
L: $0.71
H: 330.00M
A: 327.37M
L: 325.50M
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
311.94 USD
The 39 analysts offering 1 year price forecasts for PEN have a max estimate of 340.00 and a min estimate of 260.00.